e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Venous thromboembolic disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism
A. Kosma, A. Antoniadis, G. Koundi, G. Voudrislis, E. Markopoulou, E. Kalaitzidou, N. Galanis (Thessaloniki, Serres, Greece)
Source:
Annual Congress 2007 - Venous thromboembolic disease
Session:
Venous thromboembolic disease
Session type:
Thematic Poster Session
Number:
3558
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Kosma, A. Antoniadis, G. Koundi, G. Voudrislis, E. Markopoulou, E. Kalaitzidou, N. Galanis (Thessaloniki, Serres, Greece). Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism. Eur Respir J 2007; 30: Suppl. 51, 3558
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Comparison of acute phase reactant pentraksin-3 and inflammatory parameters in acute and stable pulmonary embolism
Features of patients newly diagnosed pulmonary embolism during COVID pneumonia
Indications and pitfalls of high-flow nasal cannula (HFNC) outside the intensive care unit
Related content which might interest you:
One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism
Source: Annual Congress 2003 - Pulmonary hypertension
Year: 2003
Long term treatment of pulmonary embolism (PE) with low molecular weight heparin (LMWH) (tinzaparin). Preliminary results
Source: Eur Respir J 2007; 30: Suppl. 51, 80s
Year: 2007
Low-molecular-weight heparin
versus
unfractionated heparin in acute pulmonary thromboembolism
Source: Eur Respir J 2001; 18: Suppl. 33, 381s
Year: 2001
Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism
Source: Eur Respir J 2002; 20: Suppl. 38, 237s
Year: 2002
Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE
Source: Eur Respir J 2005; 26: Suppl. 49, 699s
Year: 2005
Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism
Source: Eur Respir J 2001; 18: Suppl. 33, 382s
Year: 2001
Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Year: 2021
Pulmonary embolism and pregnancy
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177
Year: 2004
Successful heparin desensitization after anaphylactic shock due to low molecular weight heparin
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005
Possible anti-inflammatory activity of low molecular weight heparin in patients with high risk of pulmonary embolism
Source: Eur Respir J 2004; 24: Suppl. 48, 684s
Year: 2004
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis
Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism
Year: 2020
Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin.
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019
Early discharge of patients with pulmonary embolism: a two-phase observational study
Source: Eur Respir J 2007; 30: 708-714
Year: 2007
Treatment of VTE during pregnancy with a once-daily regimen of LMWH
Source: Annual Congress 2007 - Acute and chronic pulmonary embolism
Year: 2007
A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE)
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019
Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Year: 2019
Anti-inflammatory activity of low molecular weight heparin in patients with exacerbations of COPD
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Comparison of long –term outcomes of 50 mg rt-PA and 100 mg rt-PA in the management of acute pulmonary embolism
Source: International Congress 2016 – Acute pulmonary embolism
Year: 2016
Thromboprophylaxis in lung cancer patients with intermediate tinzaparin dose: The iCaLT study
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
The treatment of sub massive pulmonary embolism: Thrombolytic or heparin?
Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept